Clinical Trials Logo

Male clinical trials

View clinical trials related to Male.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05135143 Completed - Infertility Clinical Trials

Role of Antioxidants in the Reduction of Oxidative Stress in Infertile Patients

OAT
Start date: September 1, 2017
Phase: Phase 4
Study type: Interventional

Numerous studies verify that the majority of cases of male infertility belong to the group diagnosed with oligoasthenoteratozoospermia (OAT), which means a decrease in the number of sperm in the ejaculate to 15 million / ml, reduced sperm motility of the spermatozoa and morphological disorders of the neck or tail of the sperm. Genuine scientific studies can not pinpoint the cause of these changes, however, recent advances in science shed light on this issue by confirming the reason, which is as a result of the action of free radicals - oxidative stress.

NCT ID: NCT04935151 Completed - Male Clinical Trials

HoLEP vs BPRP in the Management of a Large Volume (> 80 gm) Symptomatic BPH

Start date: December 4, 2016
Phase: N/A
Study type: Interventional

To compare bipolar resection versus holmium laser enucleation for management of symptomatic large BPH (> 80 gm)

NCT ID: NCT04561050 Completed - Bleeding Clinical Trials

Prediction of Massive Transfusion in Trauma Patients

MTP
Start date: August 1, 2020
Phase:
Study type: Observational

Since the 2000s, many prognostic scores were developed to predict traumatic haemorrhage. Most of these studies were retrospectives based on registers. Due to missing data on death due to bleeding, these studies chose to predict the massive transfusion risk as a surrogate of haemorrhagic death. These scores include clinical parameters (vital signs), laboratory values (Haemoglobin, lactate, Base excess) and/or imaging (CT or ultrasound) values. The scores showing best performance are the Trauma Associated Severe Haemorrhage (TASH) score, developed and validated on the German register (DGU-Register) and the ABC score developed and validated in the United States of America. However, the majority of these scores cannot be applied at the trauma scene due to the unavailability of laboratory and imaging values. Therefore, their clinical utility remains unclear. To overcome the need for diagnostic tests, authors have developed and recently validated a clinical prognostic score in identifying trauma patients with, or at risk of, significant haemorrhage based on predicted probabilities of death due to bleeding: BATT score. This score was developed from an international cohort using data from 271 Trauma Centres in 41 countries on 5 continents and uses first clinical parameters at initial assessment. The BATT score predicts death due to bleeding and has been validated on a large population in England and Wales. It could also predict massive transfusion, as a surrogate of haemorrhagic death, earlier at the trauma scene. Its feasibility and external validation would make its clinical utility superior to other scores while identifying a greater number of patients requiring early management. Our study is an external validation of pre-existing prognostic scores of traumatic haemorrhages (TASH , ABC and BATT score) at different times of care (Scene of Injury, admission at the trauma room) in order to assess their overall performance, discrimination and calibration in the prediction of massive transfusion, and haemorrhagic death. The objective of the study is to assess a comparison of score performances (Overall performance, discrimination and calibration). Due to the study population (STR), which is partly integrated into the German DGU-Register, the investigators expect good transportability of the TASH score to the Swiss Trauma Registry in terms of overall performance, discrimination and calibration. The ABC score should show lowers results in terms of discrimination due to its validation on small cohorts exclusively in North America. The new BATT score predicting death due to bleeding has been validated on a large English cohort of more than 100,000 patients. It identifies all patients with haemorrhage and not only patients who have received a massive transfusion subject to survival bias. In this context, the BATT score provides good discrimination with only simple physiological variables available at the trauma scene. In case of its external validation on the STR as part of our study, its feasibility would make its clinical utility superior to other pre-existing scores, while identifying a greater number of patients requiring early management. Its application would activate a massive transfusion plan directly at the trauma scene and save precious time.

NCT ID: NCT04470908 Completed - Healthy Clinical Trials

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Start date: July 29, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study was to determine the effect of the moderate cytochrome P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy males.

NCT ID: NCT04443231 Completed - Myopia Clinical Trials

Prospective Clinical Study of Retinal Microvascular Alteration After ICL Implantation

Start date: November 1, 2018
Phase:
Study type: Observational

To observe the retinal microvascular alteration during 3 months follow-up after Implantable Collamer Lens (ICL) operation in moderate and high myopia patients using quantitative optical coherence tomography angiography (OCTA) analysis.

NCT ID: NCT04238650 Completed - Healthy Volunteers Clinical Trials

A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers

Start date: August 2, 2019
Phase: Phase 1
Study type: Interventional

A Randomised, Double Blind, Two-Arm, Single Dose, Parallel Phase I Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (a Proposed Bevacizumab Biosimilar Drug) and EU Approved Avastin® in Japanese Healthy Male Volunteers. During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.

NCT ID: NCT04143399 Completed - Male Clinical Trials

HoLEP vs BPRP of a Large Volume BPH: a Randomised Controlled Trial

Start date: February 14, 2016
Phase: N/A
Study type: Interventional

To compare bipolar resection versus holmium laser enucleation for management of large BPH.

NCT ID: NCT03998150 Completed - Male Clinical Trials

Holmium Laser vs Bipolar Enucleation of a Large Volume BPH: a Randomised Controlled Study

BPH
Start date: November 1, 2016
Phase: N/A
Study type: Interventional

To compare bipolar plasmakinetic enucleation versus holmium laser enucleation for management of large BPH.

NCT ID: NCT03385161 Completed - Ultrasonography Clinical Trials

Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia

Start date: December 2013
Phase: N/A
Study type: Interventional

To compare safely and efficacy of intraprostatic injection of botulinum toxin A versus ethanol for treatment of benign prostatic hyperplasia (BPH).

NCT ID: NCT02825225 Completed - Prostate Cancer Clinical Trials

A Prospective Randomized Trial of Two Different Prostate Biopsy Schemes

Start date: May 2012
Phase: N/A
Study type: Interventional

The main purpose is to compare the detection rate of 20-core versus 12-core prostate biopsy. The secondary objective is to evaluate pain perception using a validated scale to compare the analgesia provided by the two different local anesthesia schemes. Data will be prospectively collected from patients who will undergo prostate biopsy in a single high volume urology center. The patients will be randomized to two different biopsy samplings and two local anesthesia schemes.